Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price shot up 37.9% on Thursday . The stock traded as high as C$0.24 and last traded at C$0.20. 1,160,600 shares changed hands during mid-day trading, an increase of 120% from the average session volume of 528,233 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Performance
The firm has a market cap of C$17.42 million, a PE ratio of -10.00 and a beta of 0.20. The firm’s 50 day moving average price is C$0.09 and its two-hundred day moving average price is C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- Stock Splits, Do They Really Impact Investors?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- How is Compound Interest Calculated?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
